ALK-positive cancer: still a growing entity.
Future Oncol
; 10(2): 305-21, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-24490615
ABSTRACT
Since the discovery of ALK-positive anaplastic large-cell lymphoma in 1994 many other types of tumors showing ALK expression were disclosed. They form a heterogeneous group, including lung, renal and soft tissue tumors. The biological function of ALK, its role in carcinogenesis and impact exerted on the clinical outcome have been studied by many research groups. New drugs specifically dedicated for ALK inhibition, for example, crizotinib, have been synthesized and have become a viable treatment option for ALK-positive lung adenocarcinoma, and potentially for other ALK-positive cancers. This review summarizes the current state of knowledge concerning ALK-positive neoplasms, focusing on the clinical aspects of the subject.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Receptores Proteína Tirosina Quinases
/
Neoplasias
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Polônia